44 filings
8-K
Audentes Therapeutics, Inc.
15 Jan 20
Astellas Completes Acquisition of Audentes Therapeutics
10:03am
8-K
Audentes Therapeutics, Inc.
16 Dec 19
Departure of Directors or Certain Officers
6:51am
8-K
Audentes Therapeutics, Inc.
3 Dec 19
Astellas Enters into Definitive Agreement to
12:00am
8-K
Audentes Therapeutics, Inc.
7 Nov 19
Results of Operations and Financial Condition
4:06pm
8-K
Audentes Therapeutics, Inc.
8 Oct 19
Other Events
9:54pm
8-K/A
bk1gp555
23 Aug 19
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
rt2rk b1r53y
6 Aug 19
Results of Operations and Financial Condition
4:06pm
8-K
f1tqz rb919kj
28 Jun 19
Departure of Directors or Certain Officers
4:00pm
8-K
hi2s5v
7 Jun 19
Departure of Directors or Certain Officers
4:30pm
8-K
cdcu868mnm 37xqd
29 May 19
Departure of Directors or Certain Officers
4:02pm
8-K
197tfdpjpge7
7 May 19
Results of Operations and Financial Condition
4:03pm
8-K
n05ps3irzdge50dkqzn3
1 May 19
New data include 48 weeks of follow-up for six treated patients in dose Cohort 1 and 24 weeks for three treated patients in dose Cohort 2
2:15pm
8-K
iu6au0cp
8 Apr 19
Other Events
7:11am
8-K
f9vsjc3wy3mt52q5o4e
27 Feb 19
Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update
12:00am
8-K
bcuh0
6 Nov 18
Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
12:00am
8-K
5fbdnly8mgvnmjhutw00
11 Oct 18
Audentes Therapeutics Announces Pricing of Public Offering of Common Stock
4:24pm
8-K
5da8qtd
5 Oct 18
Regulation FD Disclosure
8:05am
8-K
tdr3tuuxifkjt
7 Aug 18
Results of Operations and Financial Condition
6:05am
8-K
ag5r1m
8 Jun 18
Submission of Matters to a Vote of Security Holders
5:15pm
8-K
j9o6wzpoqz 9dscz
16 May 18
Significant improvements in neuromuscular and respiratory function at 24-week timepoint
11:31am